| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-3-319-70178-3_22 |
| P698 | PubMed publication ID | 29224108 |
| P2093 | author name string | Abdulmaged M Traish | |
| P2860 | cites work | Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men | Q21132351 |
| The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance | Q22305845 | ||
| Adverse events associated with testosterone administration | Q24601802 | ||
| Metabolic complications of androgen deprivation therapy for prostate cancer | Q24616159 | ||
| The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men | Q24658075 | ||
| THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study | Q26780084 | ||
| The role of androgens in metabolism, obesity, and diabetes in males and females | Q26824343 | ||
| Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis | Q26827641 | ||
| Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? | Q28068397 | ||
| The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study | Q28261198 | ||
| Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels | Q28301408 | ||
| Contribution of dihydrotestosterone to male sexual behaviour | Q28302626 | ||
| Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment | Q45161693 | ||
| Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. | Q45168742 | ||
| Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study | Q45173585 | ||
| Endogenous sex hormones and metabolic syndrome in aging men. | Q45248596 | ||
| Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. | Q45260622 | ||
| Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. | Q45267265 | ||
| Low serum testosterone and mortality in male veterans | Q45332648 | ||
| Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. | Q45919655 | ||
| Type 2 diabetes mellitus and testosterone: a meta-analysis study. | Q45921938 | ||
| Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. | Q45930559 | ||
| Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. | Q46117635 | ||
| Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. | Q46118340 | ||
| Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. | Q46343594 | ||
| Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. | Q46570705 | ||
| Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study | Q46592977 | ||
| Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. | Q46611218 | ||
| Contribution of age and declining androgen levels to features of the metabolic syndrome in men. | Q46643531 | ||
| Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic | Q46681670 | ||
| Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. | Q46694985 | ||
| Low testosterone levels are common and associated with insulin resistance in men with diabetes. | Q46719146 | ||
| Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study | Q46757585 | ||
| Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome | Q46797284 | ||
| Testosterone making an entry into the cardiometabolic world | Q46868481 | ||
| Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy | Q46875718 | ||
| Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study | Q46881122 | ||
| Association between serum bioavailable testosterone concentration and the ratio of glycated albumin to glycated hemoglobin in men with type 2 diabetes. | Q46881271 | ||
| Low serum testosterone concentration in middle-aged men with type 2 diabetes | Q46902910 | ||
| Insulin sensitivity during combined androgen blockade for prostate cancer | Q46909972 | ||
| Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. | Q46947824 | ||
| A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate | Q46966328 | ||
| Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. | Q47253121 | ||
| Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. | Q47309640 | ||
| Testosterone Deficiency and Testosterone Treatment in Older Men. | Q47372002 | ||
| An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia | Q47596977 | ||
| Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes | Q47635024 | ||
| Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss | Q48040556 | ||
| Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels | Q48066811 | ||
| Regulation of noncontact erection in rats by gonadal steroids. | Q48183497 | ||
| Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. | Q48619033 | ||
| Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. | Q48631286 | ||
| Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. | Q48771717 | ||
| Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. | Q51035704 | ||
| Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. | Q51385645 | ||
| Is Hypoandrogenemia a Component of Metabolic Syndrome in Males? | Q51393609 | ||
| Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. | Q51464753 | ||
| The effect of testosterone on insulin sensitivity in men with heart failure. | Q51495046 | ||
| The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. | Q51495422 | ||
| Relative androgen deficiency in relation to obesity and metabolic status in older men. | Q51496427 | ||
| Testosterone concentrations in women and men with NIDDM. | Q51595541 | ||
| Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism. | Q51630094 | ||
| 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. | Q52653801 | ||
| Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. | Q53019216 | ||
| Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. | Q53211173 | ||
| Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. | Q53370836 | ||
| Transcriptomic characterization of the long-term dihydrotestosterone effects in adipose tissue. | Q53553914 | ||
| Androgen Deficiency Exacerbates High-Fat Diet-Induced Metabolic Alterations in Male Mice. | Q53809555 | ||
| Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. | Q54433748 | ||
| Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. | Q55058331 | ||
| The Effects of Chronic 5‐Alpha‐Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function | Q56700759 | ||
| Effects of Castration and Androgen Replacement on Erectile Function in a Rabbit Model1 | Q57576172 | ||
| Renal Capture and Oxidation of Cortisol in Man1 | Q57665927 | ||
| Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men | Q57927365 | ||
| Decreased Alcohol Consumption Among Former Male Users of Finasteride with Persistent Sexual Side Effects: A Preliminary Report | Q58684129 | ||
| Persistent Sexual Side Effects of Finasteride: Could They Be Permanent? | Q58684140 | ||
| Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase | Q28513566 | ||
| Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition | Q28583633 | ||
| Effect of dutasteride on the risk of prostate cancer | Q30010961 | ||
| Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia | Q30011093 | ||
| Effects of Testosterone Treatment in Older Men. | Q30833686 | ||
| Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies | Q30983590 | ||
| Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis | Q33222142 | ||
| Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium | Q33752482 | ||
| The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus | Q33853759 | ||
| Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes | Q33864913 | ||
| Testosterone concentrations in diabetic and nondiabetic obese men. | Q33873019 | ||
| Relative adrenal insufficiency in mice deficient in 5α-reductase 1 | Q33922259 | ||
| Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia | Q33961645 | ||
| Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway | Q33968194 | ||
| Identification of late-onset hypogonadism in middle-aged and elderly men. | Q34022776 | ||
| Obesity and cortisol | Q34071860 | ||
| Personalized medicine for the management of benign prostatic hyperplasia | Q34084593 | ||
| The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. | Q34097510 | ||
| Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline | Q34119261 | ||
| Testosterone and weight loss: the evidence | Q34134273 | ||
| Testosterone and metabolic syndrome: a meta-analysis study | Q34135149 | ||
| Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review | Q34144423 | ||
| Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients | Q34156061 | ||
| Persistent sexual side effects of finasteride for male pattern hair loss. | Q34171798 | ||
| Hypogonadism and androgen replacement therapy in elderly men. | Q34245288 | ||
| A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease | Q34301287 | ||
| Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation | Q34313221 | ||
| Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice | Q34316501 | ||
| The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride | Q34350952 | ||
| Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology | Q34360117 | ||
| 5α-reductase type 1 modulates insulin sensitivity in men. | Q34396472 | ||
| Adverse effects of androgen deprivation therapy and strategies to mitigate them. | Q34432516 | ||
| Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors | Q34457503 | ||
| Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis | Q37189216 | ||
| Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth | Q37196025 | ||
| Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations | Q37310024 | ||
| 5-alpha reductase inhibitors and erectile dysfunction: the connection | Q37353165 | ||
| Metabolic dysfunction in female mice with disruption of 5α-reductase 1 | Q37428499 | ||
| The dark side of testosterone deficiency: III. Cardiovascular disease | Q37431142 | ||
| Testosterone Deficiency Induces Changes of the Transcriptomes of Visceral Adipose Tissue in Miniature Pigs Fed a High-Fat and High-Cholesterol Diet | Q37534914 | ||
| Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. | Q37634014 | ||
| Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. | Q37636067 | ||
| Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity | Q37646528 | ||
| Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. | Q37694089 | ||
| Endocrine aspects of male sexual dysfunctions | Q37730212 | ||
| Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome | Q37798047 | ||
| Testosterone deficiency | Q37891357 | ||
| Onset of effects of testosterone treatment and time span until maximum effects are achieved | Q37900796 | ||
| Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment | Q38042740 | ||
| Do low testosterone levels contribute to ill-health during male ageing? | Q38055249 | ||
| 5α-reductases in human physiology: an unfolding story | Q38068013 | ||
| Testosterone: a metabolic hormone in health and disease | Q38078874 | ||
| Testosterone: a vascular hormone in health and disease | Q38095387 | ||
| A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review | Q38139618 | ||
| Androgens modulate endothelial function and endothelial progenitor cells in erectile physiology | Q38164333 | ||
| Testosterone supplementation and sexual function: a meta-analysis study | Q38201813 | ||
| Outcomes of testosterone therapy in men with testosterone deficiency (TD): part II. | Q38215115 | ||
| Adverse health effects of testosterone deficiency (TD) in men. | Q38221303 | ||
| Testosterone therapy and cardiovascular risk: advances and controversies | Q38338216 | ||
| Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment | Q38380214 | ||
| Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone | Q38380217 | ||
| Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial | Q38380236 | ||
| Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial | Q38380241 | ||
| Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial | Q38402163 | ||
| The Cardiovascular Safety of Dutasteride | Q38404318 | ||
| Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss | Q38405165 | ||
| Androgen receptor-deficient islet β-cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse | Q38435447 | ||
| Testosterone and obesity | Q38485746 | ||
| International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic | Q38639467 | ||
| The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease | Q38641840 | ||
| Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation | Q38795260 | ||
| Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis | Q38814349 | ||
| Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups | Q38830965 | ||
| Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients | Q38837659 | ||
| Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients | Q38866367 | ||
| Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined? | Q38917690 | ||
| Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. | Q39004898 | ||
| Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. | Q39107426 | ||
| Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension | Q39116956 | ||
| Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). | Q39255893 | ||
| Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. | Q39607039 | ||
| Dihydrotestosterone protects human vascular endothelial cells from H(2)O(2)-induced apoptosis through inhibition of caspase-3, caspase-9 and p38 MAPK. | Q39685042 | ||
| Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials | Q39738952 | ||
| Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study | Q39777497 | ||
| Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins | Q39967508 | ||
| Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. | Q40181524 | ||
| Prevalence of symptomatic androgen deficiency in men. | Q40183474 | ||
| Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy | Q40299247 | ||
| Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency | Q40316690 | ||
| Transdermal dihydrotestosterone treatment of 'andropause'. | Q40488399 | ||
| Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research | Q40550041 | ||
| Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels | Q40676407 | ||
| A comparison of the effects of methyltrienolone (R 1881) and 5α-dihydrotestosterone on sexual behavior of castrated male rats | Q40739373 | ||
| Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study | Q40760488 | ||
| Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study | Q40777322 | ||
| New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone | Q40985056 | ||
| Testosterone replacement attenuates mitochondrial damage in a rat model of myocardial infarction | Q41166491 | ||
| Dihydrotestosterone as a Protective Agent in Chronic Experimental Autoimmune Encephalomyelitis. | Q41234980 | ||
| Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. | Q41507830 | ||
| Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study | Q41591016 | ||
| New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. | Q41626209 | ||
| The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs | Q41849970 | ||
| Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. | Q42626533 | ||
| Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial | Q42812516 | ||
| Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study | Q43198484 | ||
| Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. | Q43198540 | ||
| Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study | Q43297274 | ||
| Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. | Q43650554 | ||
| Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study | Q43843236 | ||
| Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manage | Q43902268 | ||
| Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes | Q43959465 | ||
| Effect of obesity and body fat distribution on sex hormones and insulin in men. | Q44107806 | ||
| Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity | Q44210279 | ||
| Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations | Q44231936 | ||
| Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss | Q44245579 | ||
| Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia | Q44290482 | ||
| Testosterone replacement therapy restores normal ghrelin in hypogonadal men. | Q44582454 | ||
| Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. | Q44635140 | ||
| Sex hormones, inflammation and the metabolic syndrome: a population-based study | Q44670623 | ||
| Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone | Q44757063 | ||
| Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical Frailty | Q34458372 | ||
| Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. | Q34460537 | ||
| Testosterone and "Age-Related Hypogonadism"--FDA Concerns | Q34490131 | ||
| Facing the diabetes epidemic--mandatory reporting of glycosylated hemoglobin values in New York City | Q34492950 | ||
| Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis | Q34502187 | ||
| Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials | Q34535845 | ||
| Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia | Q34536368 | ||
| Association of Suicidality and Depression With 5α-Reductase Inhibitors | Q34553657 | ||
| Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes | Q34567831 | ||
| Androgen deprivation therapy for prostate cancer: new concepts and concerns | Q34617845 | ||
| Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors | Q34617924 | ||
| Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer | Q34617931 | ||
| Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. | Q34638122 | ||
| Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. | Q34661235 | ||
| Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. | Q34676945 | ||
| Islet beta cell failure in type 2 diabetes | Q34698810 | ||
| Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). | Q34718357 | ||
| Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance | Q34722653 | ||
| Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men | Q34724175 | ||
| The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group | Q34745427 | ||
| Glucocorticoid receptor variants: clinical implications. | Q34758698 | ||
| Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. | Q34807478 | ||
| The role of testosterone in the metabolic syndrome: a review | Q34981185 | ||
| Testosterone therapy and mortality risk | Q35033737 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes | Q35060256 | ||
| Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis | Q35087049 | ||
| Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia | Q35157640 | ||
| Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. | Q35192895 | ||
| Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results | Q35407450 | ||
| Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer | Q35433102 | ||
| Reduced cortisol metabolism during critical illness | Q35549611 | ||
| Acute testosterone deprivation reduces insulin sensitivity in men | Q35573457 | ||
| Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review | Q35810322 | ||
| 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes | Q35878846 | ||
| Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer | Q35977154 | ||
| Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions | Q36055080 | ||
| Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse | Q36094424 | ||
| Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program | Q36129822 | ||
| Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging | Q36130944 | ||
| Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man | Q36431676 | ||
| Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence | Q36471579 | ||
| Glucocorticoids and type 2 diabetes: from physiology to pathology | Q36506631 | ||
| Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat | Q36658352 | ||
| Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male | Q36892733 | ||
| Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity | Q36906339 | ||
| Are the adverse effects of glitazones linked to induced testosterone deficiency? | Q36956546 | ||
| Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss | Q37102869 | ||
| Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis | Q37113079 | ||
| Dysregulation of glucocorticoid metabolism in murine obesity: comparable effects of leptin resistance and deficiency | Q37173164 | ||
| Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. | Q37188705 | ||
| Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. | Q44816778 | ||
| Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer | Q44836371 | ||
| Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer | Q44855302 | ||
| Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. | Q44865591 | ||
| Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. | Q44883216 | ||
| The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. | Q44968760 | ||
| Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. | Q44971826 | ||
| Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia | Q45055825 | ||
| Waist circumference and testosterone levels in community dwelling men. The Tromsø study | Q45087781 | ||
| Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes | Q45142808 | ||
| The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study | Q45145832 | ||
| The influence of androgen deprivation therapy on metabolism in patients with prostate cancer | Q45161374 | ||
| Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle | Q45161400 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | testosterone | Q27863114 |
| P304 | page(s) | 473-526 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. | |
| P478 | volume | 1043 |
| Q57595107 | Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia |
| Q58749738 | Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms |
| Q90581765 | Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm |
| Q90238509 | Leydig-like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats |
| Q92229189 | Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase |
| Q89126958 | The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health |
| Q64227937 | The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis |
Search more.